Immunocore Holdings Plc · NASDAQ:IMCR
Immunocore — Q2 2022 Earnings Presentation
29 slides from Immunocore's earnings presentation, Aug 10, 2022
Slide 1: Q2 Financial Results & Business Update
Q2 FINANCIAL RESULTS & BUSINESS UPDATE WEDNESDAY, AUGUST 10, 2022
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “believe,” “expect,” “plan,” “anticipate,” “project” and similar expressions (as well as other words or expression
Slide 3: Overview & Q2 Highlights agenda
Overview & Q2 Highlights Bahija Jallal, PhD – Chief Executive Officer Q2 Financials Brian Di Donato – Chief Financial Officer & Head of Strategy KIMMTRAK® LaunchRalph Torbay – Head of Commercial Portfolio UpdateDavid Berman, MD, PhD – Head of R&D Concluding Remarks Bahija Jallal, PhD – Chief Executi
Slide 4: Harnessing the immune system to fight disease with bispecific TCRs
Harnessing the immune system to fight disease with bispecific TCRs Disease cell / target Targeted, off-the-shelf, bispecific soluble T cell receptor (TCR) Natural cytotoxic T cell with CD3 receptors
Slide 5: We are defining a new frontier of cancer treatment
We are defining a new frontier of cancer treatment T Cell Receptor (TCR) Therapy Off-the-shelf bispecific T cell engagers Chemotherapy 1949 Targeted Therapy 1997 Immunotherapy 2011 Antibody-DrugConjugate 2013 Cell Therapy 2017 2022
Slide 6: Q2 Highlights
Q2 Highlights Executing on commercial launch Following US, KIMMTRAK now approved in EU, UK, Australia and Canada Rapidly transitioned 100% of EAP patients in Germany 1st Half KIMMTRAK / tebentafusp net revenue of >$45M Expanding platform beyond uveal melanoma Cutaneous melanoma 1-yr OS data presente
Slide 7: Q2 Financials
Q2 Financials BRIAN DI DONATO CFO & Head of Strategy
Slide 8: Q2 2022 Financials (converted to USD)
Q2 2022 Financials (converted to USD) Key Figures (currency translated) Q2 2022 Q1 2022 KIMMTRAK net revenue (US) $22.1 $10.1 KIMMTRAK net revenue (Europe) $7.1 - Pre-product net revenue (France) $4.5 $3.7 Total net KIMMTRAK/ tebentafusp revenue $33.7 $13.8 Collaboration revenues $5.2 $15.7 R&D expe
Slide 9: KIMMTRAK Launch
KIMMTRAK® Launch RALPH TORBAY Head of Commercial
Slide 10: Executing on the global commercial launch of KIMMTRAK
All US (Q1) and Germany (Q2) EAP patients transitioned to commercial supply Inclusion in NCCN & ASCO1 guidelines Approvals in 30+ countries including recent approvals in UK, Australia, and Canada $46.5M in KIMMTRAK/ tebentafusp net revenue 1H 2022 1. National Comprehensive Cancer Network (NCCN) & Am
Slide 11: Establishing KIMMTRAK as 1L treatment in the US
Establishing KIMMTRAK as 1L treatment in the US ~300 accounts capture 75% of estimated mUM* market potential 124 new to KIMMTRAK accounts in US patients treated closer to home in community setting1 25% of patients are now 1L3 40% +40% of patient potential 1. Internal estimates based on KIMMTRAKConne
Slide 12: Delivering KIMMTRAK to patients in Europe
Delivering KIMMTRAK to patients in Europe Patients in Germany converted from EAP in May 2022 100% Of patients treated in France and Germany are now 1L1 30% Countries where the Expanded Access Program (EAP) is now open 10 New to KIMMTRAK accounts in France and Germany 45 Market Research data as of Ju
Slide 13: On our way to transform the lives of over 1,000 patients
On our way to transform the lives of over 1,000 patients USD millions $46.5M KIMMTRAK / tebentafusp net revenue 1H Strive to reach 1,000+ new patients by 2025 In millions. $ figures are based on "convenience" rates of 1.2162 for Q2 and 1.3152 for Q1 applied to £ figures reported.
Slide 14: Portfolio Update
Portfolio Update DAVID BERMAN Head of Research and Development
Slide 15: Building our clinical portfolio beyond KIMMTRAK approval
Building our clinical portfolio beyond KIMMTRAK approval Expanding KIMMTRAK beyond mUM KIMMTRAK in advanced melanoma Clinical stage HBV & HIV programs Entering Infectious Diseases ImmTAC candidates targeting PRAME & MAGE-A4 Evaluating platform in large oncology indications
Slide 16: Building our clinical portfolio beyond KIMMTRAK approval
Building our clinical portfolio beyond KIMMTRAK approval Expanding KIMMTRAK beyond mUM KIMMTRAK in advanced melanoma Clinical stage HBV & HIV programs Entering Infectious Diseases ImmTAC candidates targeting PRAME & MAGE-A4 Evaluating platform in large oncology indications
Slide 17: KIMMTRAK + anti-PDL1 in metastatic cutaneous melanoma
KIMMTRAK + anti-PDL1 in metastatic cutaneous melanoma Time from prior anti-PD(L)1 1-yr OS Remote 75% Immediately prior 75% Benchmark2 55% Time since last dose of prior anti-PD(L)1 does not impact OS Overall Survival (OS) by whether prior anti-PD(L)1 therapy was remote or most recent therapy1 1. Oral
Slide 18: IMCgp100-203: Phase 2/3 in previously treated, advanced melanoma
IMCgp100-203: Phase 2/3 in previously treated, advanced melanoma Randomization to ‘real world’ treatment as a control arm | Initiation of trial expected Q4 2022 Phase Primary Endpoint Per Arm Size 2 ctDNA and OS 40 3 OS 170 KIMMTRAK KIMMTRAK + anti-PD-1 R Investigator discretion on subsequent therap
Slide 19: Building our clinical portfolio beyond KIMMTRAK approval
Building our clinical portfolio beyond KIMMTRAK approval Expanding KIMMTRAK beyond mUM KIMMTRAK in advanced melanoma Clinical stage HBV & HIV programs Entering Infectious Diseases ImmTAC candidates targeting PRAME & MAGE-A4 Evaluating platform in large oncology indications
Slide 20: Insights from KIMMTRAK clinical development in mUM
Insights from KIMMTRAK clinical development in mUM Overall survival benefit Tumor Day 16 Baseline CD8 CD4 CD3 MEDIAN OS: 21.7months HAZARD RATIO: 0.51 Redirects T cells into tumor1 Durable clinical activity2 Activity at high and low H score3 ctDNA reduction4 1. Butler, et. al. AACR Annual Meeting 20
Slide 21: ImmTAC clinical candidates targeting PRAME and MAGE-A4
ImmTAC clinical candidates targeting PRAME and MAGE-A4 IMC-F106C targeting PRAME >150,000 PRAME+, HLA-A2 patients/year Biologically active doses 20+ PRAME-positive, efficacy evaluable patients IMC-C103C targeting MAGE-A4 >60,000 MAGE-A4+, HLA-A2 patients/year Durable PRs in ovarian and head & neck c
Slide 22: Building our clinical portfolio beyond KIMMTRAK approval
Building our clinical portfolio beyond KIMMTRAK approval Expanding KIMMTRAK beyond mUM KIMMTRAK in advanced melanoma Clinical stage HBV & HIV programs Entering Infectious Diseases ImmTAC candidates targeting PRAME & MAGE-A4 Evaluating platform in large oncology indications
Slide 23: Investigating the potential of a functional cure
Investigating the potential of a functional cure HBsAg transiently decreased1 Decreases coincided with transient ALT elevations1 Initial Phase 1 Single Ascending Dose data presented at EASL 2022 Congress IMC-I109V HBV Phase 1 Patient #1 Patient #2 Patient #3 1. Bourgeois, et. al. EASL 2022; 2. Progr
Slide 24: Concluding Remarks
Concluding Remarks BAHIJA JALLAL Chief Executive Officer
Slide 25: Key portfolio milestones anticipated in 2022
Key portfolio milestones anticipated in 2022 ~$393M Adjusted cash and cash equivalents1 Oncology Infectious Diseases FDA Approval FDA Approval for mUM | 1Q European Commission’s Approval for mUM | 2Q UK MHRA Approval for mUM | 2Q Australia and Canada Approval for mUM | 2Q Clinical supply agreement w
Slide 26: Our mid-year update
Our mid-year update Entering infectious disease therapeutic area Executing on commercial launch Expanding oncology platform beyond uveal melanoma Pioneering breakthrough discoveries in TCR therapeutics Projected financial runway through 20251 1. Projection based on the current business plan, include
Slide 27: Q&A Session
7 BRIAN DI DONATO Chief Financial Officer and Head of Strategy BAHIJA JALLAL, PhD Chief Executive Officer DAVID BERMAN, MD, PhD Head of Research and Development Q&A Session RALPH TORBAY Head of Commercial
Slide 28: Our pipeline
Our pipeline Leading bispecific TCR pipeline; FDA approval for KIMMTRAK® 1 Developed under a co-development/co-promotion collaboration with Genentech. 2 Program is wholly owned, development costs being provided by the Bill & Melinda Gates Foundation (BMGF), Immunocore retains all development and com
Slide 29: Slide 29